Skip to main content

Table 2 VEGF-A/VEGFR1, VEGF-A/VEGFR2, VEGF-B/VEGFR1, and VEGF-C/VEGFR2 ratios and association with clinico-pathological features in mismatch repair-proficient colorectal cancer.

From: Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer

   VEGF-A/VEGFR1 VEGF-A/VEGFR2 VEGF-B/VEGFR1 VEGF-C/VEGFR2
    P-value   P-value   P-value   P-value
TNM stage I+II 13.7 ± 32.6;
1.0
0.198 1.63 ± 8.6;
1.0
0.005 11.2 ± 27.2;
1.0
0.867 2.6 ± 9.3;
0.8
0.003
  III 13.0 ± 31.7;
1.0
  0.66 ± 0.4;
0.95
  8.1 ± 23.2;
1.0
  0.58 ± 0.38;
0.68
 
  IV 5.2 ± 19.7;
1.0
  3.85 ± 16.3;
1.0
  5.9 ± 20.0;
1.0
  1.95 ± 8.8;
0.84
 
Tumour grade G1-2 10.7 ± 29.2;
1.0
0.704 2.05 ± 10.6;
1.0
0.179 8.0 ± 22.9;
0.98
0.956 1.51 ± 8.2;
0.79
0.06
  G3 13.5 ± 32.2;
1.0
  0.73 ± 0.4;
0.95
  12.9 ± 29.7;
1.0
  0.58 ± 0.4;
0.65
 
Vascular invasion Absent 13.2 ± 32.2;
1.0
0.276 2.2 ± 11.3;
1.0
0.38 10.7 ± 26.9;
1.0
0.078 1.6 ± 8.9;
0.75
0.412
  Present 6.48 ± 22.0;
1.0
  0.78 ± 0.36;
0.98
  4.28 ± 15.2;
0.95
  0.65 ± 0.38;
0.75
 
Tumour border configuration PM 12.4 ± 31.2;
1.0
0.211 1.35 ± 6.3;
1.0
0.006 9.8 ± 25.2;
1.0
0.244 1.2 ± 5.7;
0.79
0.326
  IM 9.83 ± 27.6;
1.0
  2.28 ± 12.2;
0.95
  7.76 ± 23.2;
0.95
  1.48 ± 9.04;
0.75
 
PTL infiltration Absent 9.73 ± 27.6;
1.0
0.032 1.56 ± 8.4;
1.0
0.074 8.09 ± 23.5;
1.0
0.356 1.01 ± 4.5;
0.78
0.235
  Present 17.5 ± 36.6;
1.0
  2.83 ± 13.6;
1.0
  12.3 ± 27.5;
0.87
  2.79 ± 14.7;
0.75
 
  1. Mean ± SD, median values. Kruskal Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic.